TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03826810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ART
Description: Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ART
Description: Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
Study: NCT02440542

Intervention type: OTHER
Intervention: Survey of outcomes following popliteal nerve block
Description: Patients will be instructed to complete journals of pain and narcotic use until postoperative day 10. On first follow-up visit, patients will complete a patient satisfaction survey. VAS Pain scores and pain medication use will be collected up to 12 weeks postoperatively.
Study: NCT00940680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Losartan
Description: amlodipine/losartan 5/100mg q.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: losartan 100mg q.d.
Study: NCT04692766

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH-104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), 5 mL in a polypropylene ampoule, 10 ampoules per labeled package
Study: NCT01892085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early initiation
Description: Initiation of breast milk expression \<1 hour following delivery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermediate expression
Description: Initiation of milk expression 1-\<3 hours following delivery.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Late initiation
Description: Initiation of milk expression \>3-6 hours following delivery.
Study: NCT02978859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD516
Description: Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, potent small molecular inhibitor of several related receptor tyrosine kinases.
Study: NCT00645125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefdinir (Omnicef)
Description: 2.5 ml of strawberry cream flavored oral suspension 125 mg/5 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Description: 2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 mL
Study: NCT03711149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity monitor feedback loop
Description: The intervention arm will test if the feedback system (i.e., activity monitor, real-time feedback, and art tours) increases daily step count, decreases length of stay, and improves patient and provider communication, patient awareness of step count goals, and patient confidence in accomplishment of daily goals.
Study: NCT02550392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: A time-limited group psychoeducational intervention that will aim to offer educational, psychological and social support.
Study: NCT03187067

Intervention type: DEVICE
Intervention: Lung ultrasound
Description: Lung ultrasound will be performed on all children to investigate imaging patterns characteristic of pneumonia.

Intervention type: DEVICE
Intervention: Lung ultrasound
Description: Lung ultrasound will be performed on all children to investigate imaging patterns characteristic of pneumonia.

Intervention type: DEVICE
Intervention: Lung ultrasound
Description: Lung ultrasound will be performed on all children to investigate imaging patterns characteristic of pneumonia.

Intervention type: DEVICE
Intervention: Lung ultrasound
Description: Lung ultrasound will be performed on all children to investigate imaging patterns characteristic of pneumonia.
Study: NCT00570349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide for Inhalation
Description: Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide for Inhalation
Description: Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen
Description: 100% nitrogen (placebo) will be administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
Study: NCT01764997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for sarilumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for etanercept)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for etanercept)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
Study: NCT01319851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: 0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacept was diluted in sterile water (2 ml total volume) and administered via i.v. push followed by a normal saline flush per package insert.
Study: NCT02863510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Sympathetic Denervation
Description: Renal sympathetic denervation is a minimally invasive, endovascular catheter-based procedure using radiofrequency ablation of sympathetic nerves located in the walls of renal arteries, aimed at treating treatment-resistant hypertension.
Study: NCT01170637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 200 mg oral administration (RhinAdvil(R))

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 200 mg oral administration (BI product)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine-HCl
Description: 30 mg oral administration (BI product)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine-HCl
Description: 30 mg oral administration (RhinAdvil(R))
Study: NCT02222597

Intervention type: DEVICE
Intervention: infrascanner
Study: NCT04695951

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Renalof
Description: A total of 120 patients treated with the study product Renalof® at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 35 patients treated with Placebo at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
Study: NCT02232854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression training/supervision program
Description: The intervention will be composed of:~* Training of Primary Health Care teams to ensure compliance to the Clinical Guidelines of the Ministry of Health for the Treatment of Depression. Primary Health Care teams will undergo an Objective Structured Clinical Examination (OSCE) for evaluation.~* After the training, a focus group between Primary Health Care teams and study researchers will be held in order to address barriers to clinical guidelines implementation.~* Primary Health Care clinics' trained administrative staff will contact patients from a call-center to support treatment adherence.~* Psychiatrists, using a web-based platform, will supervise the course of the program, the allocated treatments, the patients' progress, and their response to treatment.
Study: NCT03015181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB075-00-AB
Description: VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB075-00-AB
Description: VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB075-00-AB
Description: VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB075-00-AB
Description: VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
Study: NCT03526471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omega™ Left Atrial Appendage (LAA) Occluder
Description: catheter delivery of Omega device in the left atrial appendage
Study: NCT01260142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol disodium, propofol
Description: Two Treatment Periods: fospropofol disodium 6.5 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 0.65 mg/kg IV bolus, or propofol injectable emulsion 0.65 mg/kg IV bolus followed by fospropofol disodium 6.5 mg/kg IV bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol disodium, propofol
Description: Two Treatment Periods: fospropofol disodium 10.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.0 mg/kg IV bolus, or propofol injectable emulsion 1.0 mg/kg IV bolus followed by fospropofol disodium 10.0 mg/kg IV bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol disodium, propofol
Description: Two Treatment Periods: fospropofol disodium 15.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.5 mg/kg IV bolus, or propofol injectable emulsion 1.5 mg/kg IV bolus followed by fospropofol disodium 15.0 mg/kg IV bolus.
Study: NCT01123512

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebral augmentation
Description: Vertebral augmentation for one or two osteoporotic vertebral compression fractures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vertebral augmentation
Description: Vertebral augmentation for one or two osteoporotic vertebral compression fractures
Study: NCT04344756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin or unfractionated heparin
Description: Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min, Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days
Study: NCT03069014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400mg LM11A-31-BHS
Description: 1 Oral Capsules (200mg of LM11A-31-BHS and 200mg of placebo) twice daily (morning \& evening) for 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 800mg LM11A-31-BHS
Description: 2 Oral Capsules (200mg of LM11A-31-BHS) twice daily (morning \& evening) for 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: 2 Oral Capsules (200mg of Placebo) twice daily (morning \& evening) for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 2 Oral Capsules (200mg of Placebo) twice daily (morning \& evening) for 26 weeks
Study: NCT00747045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation Strategy
Description: Comparison of low vs standard tidal volumes in patients undergoing PTE

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation Strategy
Description: Comparison of low vs standard tidal volumes in patients undergoing PTE
Study: NCT01592383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study: NCT01128140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: MET, a 30-60 minute telephone session, seeks to increase motivation for change by highlighting inconsistencies between substance use behaviors and beliefs and negative consequences experienced as a result of the behaviors. The counselor will guide the participant in reviewing the Personal Feedback Report (PFR), using MI strategies to elicit the participant's reactions and foster motivation for change. The PFR will show the participant's self-reported alcohol and drug use behavior, consequences of SA, and the participant's perceived and actual descriptive norms for SA behavior. The second phase will target strengthening commitment to change. Counselors will explore with participants the pros and cons of seeking treatment. As the participant verbalizes potential benefits of learning more about treatment, the counselor will use MI skills to encourage elaboration of his/her thinking with the goal of tipping the scale toward a decision to consider taking steps toward treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants will receive educational information on the health, psychological, social, and legal consequences of substance abuse. Included in the session will be: legal and behavioral definitions of SA, the social and legal consequences of SA, impact of SA on military duty, a review of the policies on substance use in the military, and treatment resources. The session will be conducted via the telephone and will last from 30-60 minutes. Counselors will present information in a didactic manner and will avoid the use of Motivational Interviewing skills (reflective listening, developing discrepancy, reinforcing participant statements regarding change).
Study: NCT01379261

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cooling
Description: 1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
Study: NCT04804228

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical dry needling
Description: The experimental group consisting of 40 subjects will perform electrostimulation on the active myofascial trigger points of the following muscles: quadratus lumbar, multifidus and iliocostalis. The electrostimulation of the PGM will be carried out using needle electrodes, the generated current will be produced by a TENS device with a frequency of 2 Hz and a pulse width of 250 μs, the application will be approximately 30 min. The therapeutic intervention will be 1 session per week for a total of 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression, analytical stretching and postural habits educational dossier
Description: The control group G2, formed by 40 subjects, will perform an ischemic compression technique in active PGM with a time between 20 seconds and 1 minute until pain inhibition is achieved, and finally, analytical stretching will be carried out on the quadratus lumbar, multifidus and iliocostal muscles, 1 weekly session for 6 weeks, in addition to providing them with a training dossier on postural education in their activities of daily life.
Study: NCT04070183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POST Facilitation
Description: Advanced steps is initiated as a component of quality end-of-life care for frail elders and those whose death in the next 12 months would not be unexpected. The AS planning conversation is focused on goals of care to make timely, proactive, and specific end-of-life decisions. Ideally, these decisions are converted into medical orders that can be followed throughout the continuum of care. The Physician Orders for Life-Sustaining Treatment (POLST) program is the nationally recognized model for this stage of planning.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home Safety Evaluation
Description: Nurse evaluation and education on how to improve safety at home for community dwelling older adults (examples of education and evaluation includes fall risks, fire and carbon monoxide (CO) detectors, transferring safety (e.g. in and out of the tub, bed, etc.) and others.
Study: NCT00657475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin Low Dose
Description: Loading heparin dose of 150 IU / kg to achieve an ACT (activating clotting time) target more than 240 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Full Dose
Description: Loading heparin dose of 300 IU / kg to achieve an ACT (activating clotting time) target more than 400 seconds.
Study: NCT01557699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PMV via Puffhaler® device
Description: The vaccine will be administered via a Puffhaler® device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PMV via SoloventTM device
Description: The vaccine will be administered via SoloventTM device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Subcutaneous Measles Vaccine
Description: This is a licensed formulation containing the live attenuated Edmonston Zagreb virus. A single dose of 0.5 ml will be given subcutaneously.
Study: NCT01002547

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone-placebo
Description: This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: Pioglitazone will be started on 30 mg/day, titrated to the maximal dose (45 mg/day) at two months and continued at this dose for the rest of the clinical trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: All participants will receive vitamin E 400 IU orally twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: pioglitazone-placebo
Description: This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin E
Description: All participants will receive vitamin E 400 IU orally twice daily.
Study: NCT02495194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horticultural Therapy
Description: The Horticultural Therapy intervention consists of 1 hour sessions weekly for first 3 months, followed by monthly session for the next 3 months. They will be taught on the basic gardening techniques such as sowing, weeding and fertilization during the hands-on sessions. They will also be taken on walks to the various parks to enjoy the therapeutic effect of the park greenery

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Horticultural Therapy
Description: The Horticultural Therapy intervention consists of 1 hour sessions weekly for first 3 months, followed by monthly session for the next 3 months. They will be taught on the basic gardening techniques such as sowing, weeding and fertilization during the hands-on sessions. They will also be taken on walks to the various parks to enjoy the therapeutic effect of the park greenery
Study: NCT05002517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tociliziumab group
Description: Tocilizumab is a humanized recombinant IgG1 monoclonal antibody to human interleukin-6 (IL-6) receptor, produced in Chinese hamster ovary cells by recombinant DNA technology.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone group
Description: Methylprednisolone belongs to a group of medicines called corticosteroids (it works at the cellular level by reducing the production of substances that cause inflammation or allergy).
Study: NCT02041650

Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor
Study: NCT01087840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Drug: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 28 days along with Tenofovir disoproxil fumarate/emtricitabine 300mg/200mg 1 tablet taken orally once daily with or without food for 28 days.~Arms: Raltegravir/Truvada Other Names: Isentress/Truvada